United States Biotechnology & Medical Research

Artiva Biotherapeutics Inc (ARTV)

Track

Artiva Biotherapeutics Inc. has seen significant insider activity over the past 90 days, characterized by substantial net buying. RA Capital Management, L.P. has been the primary driver, executing numerous large-scale purchases. While executives have engaged in minor net selling, the overall trend reflects strong institutional accumulation despite a 10.5% decline in stock price.
Ticker: ARTV Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Artiva Biotherapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 31 Jul 2026
Value US$4,658,043.02 | Price 75.67 | Shares 83,694 (+21.7%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-31 2026-07-31 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
83,694 +21.7%
75.67
US$4,658,043 		83,694 +21.7% 75.67 US$4,658,043
2026-07-31 2026-07-29 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
77,559 +37.4%
155.56
US$897,189 		77,559 +37.4% 155.56 US$897,189
2026-07-28 2026-07-24 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
13,850 -15.2%
416.49
US$4,573,214 		13,850 -15.2% 416.49 US$4,573,214
2026-07-23 2026-07-23 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
59,880 +0.3%
9.96
US$596,405 		59,880 +0.3% 9.96 US$596,405
2026-07-23 2026-07-22 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
84,124 +0.5%
9.93
US$835,351 		84,124 +0.5% 9.93 US$835,351
2026-07-23 2026-07-21 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
120,582 +0.7%
9.55
US$1,151,558 		120,582 +0.7% 9.55 US$1,151,558
2026-07-20 2026-07-17 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
7,882 +0.0%
8.95
US$70,544 		7,882 +0.0% 8.95 US$70,544
2026-07-20 2026-07-16 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
152,472 +0.9%
8.93
US$1,361,575 		152,472 +0.9% 8.93 US$1,361,575
2026-07-14 2026-07-13 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
6,552 +0.0%
8.94
US$58,575 		6,552 +0.0% 8.94 US$58,575
2026-07-14 2026-07-10 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
15,102 +0.1%
8.97
US$135,465 		15,102 +0.1% 8.97 US$135,465
2026-06-29 2026-06-26 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,876 +0.0%
8.98
US$16,846 		1,876 +0.0% 8.98 US$16,846
2026-06-29 2026-06-25 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
31,000 +0.2%
8.88
US$275,280 		31,000 +0.2% 8.88 US$275,280
2026-06-16 2026-06-16 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
124,893 +0.8%
8.89
US$1,110,299 		124,893 +0.8% 8.89 US$1,110,299
2026-06-16 2026-06-15 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
15,414 +0.1%
8.99
US$138,572 		15,414 +0.1% 8.99 US$138,572
2026-06-16 2026-06-12 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
391,019 +2.4%
8.57
US$3,351,033 		391,019 +2.4% 8.57 US$3,351,033
2026-06-11 2026-06-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
548,580 +3.5%
7.91
US$4,339,268 		548,580 +3.5% 7.91 US$4,339,268
2026-06-11 2026-06-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
548,580 +3.5%
7.91
US$4,339,268 		548,580 +3.5% 7.91 US$4,339,268
2026-06-11 2026-06-10 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
103 +0.0%
7.00
US$721 		103 +0.0% 7.00 US$721
2026-06-11 2026-06-10 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
103 +0.0%
7.00
US$721 		103 +0.0% 7.00 US$721
2026-06-11 2026-06-09 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
479,039 +3.2%
6.91
US$3,310,159 		479,039 +3.2% 6.91 US$3,310,159
2026-05-19 2026-05-19 S Sale
Horan Christopher

Chief Tech Operations Officer

Officer
7,002 -2.3%
9.01
US$63,073 		7,002 -2.3% 9.01 US$63,073
2026-05-19 2026-05-19 S Sale
Aslan Fred

Chief Executive Officer

Executive Director
27,116 -1.7%
9.01
US$244,253 		27,116 -1.7% 9.01 US$244,253
2026-05-19 2026-05-19 S Sale
Banerjee Subhashis

Chief Medical Officer

Officer
7,037 -4.6%
9.01
US$63,386 		7,037 -4.6% 9.01 US$63,386
2026-05-19 2026-05-19 S Sale
Bush Jennifer

COO, CLO, Compliance Officer

Officer
8,790 -2.5%
9.01
US$79,179 		8,790 -2.5% 9.01 US$79,179
2026-05-19 2026-05-19 S Sale
Raymon Heather

SVP, Research and Development

Officer
3,095 -2.0%
9.01
US$27,879 		3,095 -2.0% 9.01 US$27,879
2026-05-18 2026-05-18 PrS Proposed sale
Fred Aslan, M.D.

Officer; Director

Executive Director
28,000
9.22
US$258,160 		28,000 9.22 US$258,160
2026-05-18 2026-05-18 PrS Proposed sale
Subhashis Banerjee

Officer; Director

Executive Director
7,000
9.22
US$64,540 		7,000 9.22 US$64,540
2026-05-18 2026-05-18 PrS Proposed sale
Jennifer Bush

Officer; Director

Executive Director
9,000
9.22
US$82,980 		9,000 9.22 US$82,980
2026-05-18 2026-05-18 PrS Proposed sale
Heather Raymon

Officer; Director

Executive Director
3,500
9.22
US$32,270 		3,500 9.22 US$32,270
2026-05-18 2026-05-18 PrS Proposed sale
Christopher P. Horan

Officer; Director

Executive Director
7,500
9.22
US$69,150 		7,500 9.22 US$69,150
2026-05-28 2026-05-11 B Purchase
0.9
GC Corp.
Large shareholder
347,222 +27.5%
11.52
US$3,999,997 		347,222 +27.5% 11.52 US$3,999,997
2026-05-28 2026-05-11 B Purchase
0.9
GC Corp.
Large shareholder
1,085,069 +32.8%
11.52
US$12,499,995 		1,085,069 +32.8% 11.52 US$12,499,995
2026-05-13 2026-05-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
6,510,416 +74.9%
11.52
US$74,999,992 		6,510,416 +74.9% 11.52 US$74,999,992
2025-12-15 2025-12-15 PrS Proposed sale
FRED ASLAN

Director; Officer

Executive Director
12,749
3.30
US$42,072 		12,749 3.30 US$42,072
2025-12-15 2025-12-15 PlS Planned sale
Aslan Fred

President and CEO

Executive Director
3,187 -0.3%
6.00
US$19,122 		3,187 -0.3% 6.00 US$19,122
2025-11-17 2025-11-17 PrS Proposed sale
FRED ASLAN

Director; Officer

Executive Director
6,375
3.25
US$20,719 		6,375 3.25 US$20,719
2025-11-17 2025-11-17 PlS Planned sale
Aslan Fred

President and CEO

Executive Director
6,375 -1.8%
3.38
US$21,522 		6,375 -1.8% 3.38 US$21,522
2025-10-17 2025-10-17 PrS Proposed sale
FRED ASLAN

Director; Officer

Executive Director
25,500
2.77
US$70,635 		25,500 2.77 US$70,635
2025-10-17 2025-10-17 PlS Planned sale
Aslan Fred

President and CEO

Executive Director
25,500 -6.7%
6.00
US$153,000 		25,500 -6.7% 6.00 US$153,000
2025-08-18 2025-08-15 PlS Planned sale
Aslan Fred

President and CEO

Executive Director
25,500 -6.2%
2.73
US$69,579 		25,500 -6.2% 2.73 US$69,579
2025-08-15 2025-08-15 PrS Proposed sale
FRED ASLAN

Director; Officer

Executive Director
25,500
2.70
US$68,850 		25,500 2.70 US$68,850
2024-07-24 2024-07-22 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
688,326 +497.0%
12.00
US$8,259,912 		688,326 +497.0% 12.00 US$8,259,912
2024-07-24 2024-07-22 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
7,645,007 +729.1%
12.00
US$91,740,084 		7,645,007 +729.1% 12.00 US$91,740,084
2024-07-24 2024-07-22 B Purchase
2.6
5AM Partners VI, LLC
Large shareholder
833,333 +239.0%
12.00
US$9,999,996 		833,333 +239.0% 12.00 US$9,999,996
2024-07-22 2024-07-22 B Purchase
0.9
GC Corp.
Large shareholder
416,666 +49.4%
12.00
US$4,999,992 		416,666 +49.4% 12.00 US$4,999,992
2024-07-22 2024-07-22 B Purchase
0.9
GC Corp.
Large shareholder
1,666,666 +101.6%
12.00
US$19,999,992 		1,666,666 +101.6% 12.00 US$19,999,992
2024-07-22 2024-07-22 B Purchase
2.9
venBio Global Strategic Fund III, L.P.
Large shareholder
416,666 +27.4%
12.00
US$4,999,992 		416,666 +27.4% 12.00 US$4,999,992
2024-07-22 2024-07-22 B Purchase
0.8
Huh Yong-Jun
Non-Executive Director
416,666 +49.4%
12.00
US$4,999,992 		416,666 +49.4% 12.00 US$4,999,992
2024-07-22 2024-07-22 B Purchase
0.8
Huh Yong-Jun
Non-Executive Director
1,666,666 +101.6%
12.00
US$19,999,992 		1,666,666 +101.6% 12.00 US$19,999,992
Explore more

More insider trading research around Artiva Biotherapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America